Medication info
Dapagluem Sustained Release Tablet 10/1000 mg

Dapagluem Sustained Release Tablet 10/1000 mg

Prescription medicationTabletOral
Ingredient · strength
Dapagliflozin Propanediol Hydrate›12.3mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Samik Pharmaceutical Co., Ltd.
Appearance
Yellow, biconvex, oval-shaped sustained-release film-coated tablet
Packaging
Bottle packaging - 30 tablets/bottle [(bottle: HDPE, cap: LDPE)], bottle packaging - 100 tablets/bottle [(bottle: HDPE, cap: LDPE)]
Approval status
Active

MFDS item code 202300275 · Approved 2023.01.17 · Insurance code 644004690

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes
Who takes it
Adults
Adult dose
The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg. Patients who have not previously received antidiabetic drug therapy and whose glycemic control is inadequate with monotherapy: When used as initial therapy in patients who have not previously received antidiabetic drug therapy, the recommended starting dose of this medicine is 1 tablet of 5mg/500mg or 10mg/500mg once daily. Titrate the dose gradually to reduce gastrointestinal adverse reactions from metformin. For patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this medicine should provide the dose of metformin the patient was taking or an appropriate dose therapeutically close to it. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. For patients switching from combination therapy with dapagliflozin and metformin to this medicine, treatment may be started at the doses of dapagliflozin and metformin they were previously receiving. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this medicine have not been specifically evaluated in patients switching from another antihyperglycemic agent. Because changes may cause alterations in glycemic control, any change in the treatment of patients with type 2 diabetes should be made under careful monitoring. This medicine must be swallowed whole and must not be crushed, cut, or chewed. Occasionally, the inactive ingredients of this medicine may be excreted in the stool as a soft, hydrated mass resembling the tablet. Renal impairment No dose adjustment is required in patients with mild renal impairment. In patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher but below 60 mL/min/1.73 m2, and who have no other symptoms that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medicine is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, this medicine must be discontinued immediately. Renal function should be assessed every 3~6 months. Elderly patients Because metformin is excreted by the kidneys and renal function tends to decline in elderly patients, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Elderly Patients).

Ingredients

Manufacturer
Samik Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes

  • Type 2 diabetes
  • impaired blood sugar control
  • cardiovascular disease
  • cardiovascular risk factors
View approved original text

This medication helps control blood sugar in adult patients with type 2 diabetes who are using dapagliflozin and metformin in conjunction with diet and exercise therapy. The efficacy on the occurrence of cardiovascular events is also considered, particularly in patients with cardiovascular disease or risk factors where blood sugar control is insufficient. For more details, please refer to professional clinical trial information. This medication is used to improve blood sugar control in patients with type 2 diabetes.

How to take

Adult dose

The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg. Patients who have not previously received antidiabetic drug therapy and whose glycemic control is inadequate with monotherapy: When used as initial therapy in patients who have not previously received antidiabetic drug therapy, the recommended starting dose of this medicine is 1 tablet of 5mg/500mg or 10mg/500mg once daily. Titrate the dose gradually to reduce gastrointestinal adverse reactions from metformin. For patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this medicine should provide the dose of metformin the patient was taking or an appropriate dose therapeutically close to it. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. For patients switching from combination therapy with dapagliflozin and metformin to this medicine, treatment may be started at the doses of dapagliflozin and metformin they were previously receiving. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this medicine have not been specifically evaluated in patients switching from another antihyperglycemic agent. Because changes may cause alterations in glycemic control, any change in the treatment of patients with type 2 diabetes should be made under careful monitoring. This medicine must be swallowed whole and must not be crushed, cut, or chewed. Occasionally, the inactive ingredients of this medicine may be excreted in the stool as a soft, hydrated mass resembling the tablet. Renal impairment No dose adjustment is required in patients with mild renal impairment. In patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher but below 60 mL/min/1.73 m2, and who have no other symptoms that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medicine is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, this medicine must be discontinued immediately. Renal function should be assessed every 3~6 months. Elderly patients Because metformin is excreted by the kidneys and renal function tends to decline in elderly patients, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Elderly Patients).

Precautions

This medication is used to help control blood sugar and is mainly used in patients with diabetes. However, it should not be administered to patients with poor kidney function or those with severe infections or dehydration. This medication can rarely cause a serious metabolic complication called lactic acidosis, so patients and healthcare providers should be well aware of the symptoms of lactic acidosis. Also, there is a risk of hypoglycemia when used in combination with insulin or sulfonylureas, so caution is needed. This medication is not recommended for patients with moderate to severe impaired kidney function, and kidney function should be regularly monitored before and during treatment. Elderly patients or those with reduced fluid volume are at higher risk of dehydration or hypotension, so blood pressure and fluid status should be closely monitored. Additionally, this medication may increase the risk of genital and urinary tract infections, and immediate treatment should be sought if symptoms of infection appear. Women who are pregnant or breastfeeding should not use this medication, and treatment should be discontinued immediately if pregnancy is confirmed. Excessive alcohol consumption may increase the risk of lactic acidosis when taking this medication, so it should be avoided. If surgery or contrast agent examination is planned during the treatment period, it is necessary to consult the healthcare provider to consider discontinuation for a period. Also, this medication can cause vitamin B12 deficiency in some patients, so regular blood tests are recommended. Hypoglycemia symptoms may occur, so patients should pay attention to symptoms such as dizziness or lightheadedness, and consult a physician immediately if symptoms occur. This medication is not established for safety and efficacy in children, so it should not be used. Finally, this medication should be stored out of reach of children and kept in the original container to maintain quality.

Side effects

  • Severe lactic acidosis
  • severe hypoglycemia
  • vulvovaginitis
  • balanitis
  • genital infections
  • urinary tract infections
  • fungal infections
  • hypoglycemia
  • decreased fluid volume
  • thirst
Show 84 more
  • diabetic ketoacidosis
  • dizziness
  • constipation
  • dry mouth
  • lower back pain
  • dysuria
  • polyuria
  • nocturia
  • vulvar pruritus
  • genital pruritus
  • increased hematocrit
  • decreased renal creatinine clearance
  • dyslipidemia
  • elevated serum creatinine
  • elevated blood urea
  • weight loss
  • ketoacidosis
  • urosepsis
  • pyelonephritis
  • acute kidney injury
  • renal dysfunction
  • rash
  • diarrhea
  • nausea
  • vomiting
  • decreased vitamin B12
  • Guillain-Barré syndrome
  • bacterial pneumonia
  • sialadenitis
  • tendinitis
  • chest pain
  • thermal burns
  • wrist fractures
  • gastrointestinal stromal tumors
  • malignant neoplasm of the lung
  • uterine fibroids
  • atrial fibrillation
  • acute cholecystitis
  • upper abdominal pain
  • dyspepsia
  • abdominal discomfort
  • abdominal pain
  • gastric ulcer
  • irritable bowel syndrome
  • salivary gland masses
  • toothache
  • headache
  • facial paralysis
  • peripheral neuropathy
  • sensory disturbance
  • drowsiness
  • tremors
  • nasopharyngitis
  • pharyngitis
  • adenoviral conjunctivitis
  • shingles
  • pneumonia
  • rhinitis
  • elevated alanine aminotransferase
  • increased blood sugar
  • arthralgia
  • myalgia
  • myofascial pain syndrome
  • osteoarthritis
  • osteochondrosis
  • limb pain
  • periartritis
  • tendinitis
  • trigger finger
  • weakness
  • fatigue
  • peripheral edema
  • edema
  • pain
  • vitamin D deficiency
  • hyperglycemia
  • urethral syndrome
  • cough
  • hyperventilation
  • pruritus
  • palpitations
  • insomnia
  • type 2a hyperlipidemia
  • sensorineural hearing loss

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to prevent air or moisture from entering. It is recommended to maintain storage temperatures between 1°C and 30°C at room temperature.

Appearance and packaging

Appearance

Yellow, biconvex, oval-shaped sustained-release film-coated tablet

Package unit

Bottle packaging - 30 tablets/bottle [(bottle: HDPE, cap: LDPE)], bottle packaging - 100 tablets/bottle [(bottle: HDPE, cap: LDPE)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.